FGFR4 and hepatocellular carcinoma: Therefore, PD173074, a tyrosine kinase inhibitor, may function in HepG2 and Hep3B by targeting FGFR4 and our data demonstrate that PD173074 affects G1/S checkpoint and inhibits cell proliferation largely via repressing FGFR4 activity in these HCC cells.